ELI LILLY AND COMPANY Line of Credit Facility, Maximum Borrowing Capacity
ELI LILLY AND COMPANY (LLY) had Line of Credit Facility, Maximum Borrowing Capacity of $1.20 billion as of 2011-06-30, per its 10-Q filed 2011-07-29.
Discontinued › Notes › Debt › Line of Credit Facility
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity · last filed 2011-10-28
- 2011-06-30: Line of Credit Facility, Maximum Borrowing Capacity $1.20B.
- 2011-04-30: Line of Credit Facility, Maximum Borrowing Capacity $1.20B.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity |
|---|---|
| 2011-06-30 | $1.20B 10-Q · filed 2011-07-29 |
| 2011-04-30 | $1.20B 10-Q · filed 2011-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |